The role of autoantibody-producing plasma cells in immune thrombocytopenic purpura refractory to rituximab

Abstract

Rituximab is becoming popular as a treatment for immune thrombocytopenic purpura (ITP). We report here a patient with ITP, who initially responded to rituximab, but later became refractory. In this patient, the appearance of plasma cells producing anti-platelet autoantibodies is likely to be one of the mechanisms for rituximab resistance. © 2007 Wiley-Liss, Inc.